LT3952872T - Karbamoilcikloheksano dariniai, skirti autizmo spektro sutrikimo gydymui - Google Patents
Karbamoilcikloheksano dariniai, skirti autizmo spektro sutrikimo gydymuiInfo
- Publication number
- LT3952872T LT3952872T LTEPPCT/IB2020/053382T LTIB2020053382T LT3952872T LT 3952872 T LT3952872 T LT 3952872T LT IB2020053382 T LTIB2020053382 T LT IB2020053382T LT 3952872 T LT3952872 T LT 3952872T
- Authority
- LT
- Lithuania
- Prior art keywords
- autism spectrum
- spectrum disorder
- cyclohexane derivatives
- treating autism
- carbamoyl
- Prior art date
Links
- 208000029560 autism spectrum disease Diseases 0.000 title 1
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical class NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1900121A HU231500B1 (hu) | 2019-04-10 | 2019-04-10 | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
| PCT/IB2020/053382 WO2020208564A1 (en) | 2019-04-10 | 2020-04-09 | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3952872T true LT3952872T (lt) | 2024-05-27 |
Family
ID=89992883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/IB2020/053382T LT3952872T (lt) | 2019-04-10 | 2020-04-09 | Karbamoilcikloheksano dariniai, skirti autizmo spektro sutrikimo gydymui |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP3952872B1 (lt) |
| JP (1) | JP2022527386A (lt) |
| KR (1) | KR20210151162A (lt) |
| CN (1) | CN113677345A (lt) |
| AR (1) | AR118634A1 (lt) |
| AU (1) | AU2020271363A1 (lt) |
| BR (1) | BR112021019367A2 (lt) |
| CL (1) | CL2021002632A1 (lt) |
| DK (1) | DK3952872T3 (lt) |
| EA (1) | EA202192717A1 (lt) |
| ES (1) | ES2980780T3 (lt) |
| FI (1) | FI3952872T3 (lt) |
| GE (1) | GEP20237554B (lt) |
| HR (1) | HRP20240772T1 (lt) |
| HU (2) | HU231500B1 (lt) |
| IL (1) | IL287076A (lt) |
| LT (1) | LT3952872T (lt) |
| MX (1) | MX2021012321A (lt) |
| PL (1) | PL3952872T3 (lt) |
| PT (1) | PT3952872T (lt) |
| RS (1) | RS65530B1 (lt) |
| SG (1) | SG11202110421YA (lt) |
| SI (1) | SI3952872T1 (lt) |
| TW (1) | TW202103701A (lt) |
| UY (1) | UY38657A (lt) |
| WO (1) | WO2020208564A1 (lt) |
| ZA (1) | ZA202108429B (lt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114588162B (zh) * | 2022-03-30 | 2023-10-27 | 中国人民解放军空军军医大学 | 拉莫三嗪治疗孤独症触觉异常的应用 |
| US11980603B2 (en) | 2022-06-11 | 2024-05-14 | AMS Therapeutics, LLC | Method of treating expressive language deficit in autistic humans |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227534B1 (en) | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| EA017732B1 (ru) | 2007-05-11 | 2013-02-28 | Рихтер Гедеон Нирт. | Сольватная и кристаллическая формы гидрохлорида транс-1{4-[2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил]циклогексил}-3,3-диметилмочевины, способы их получения и их применение в фармацевтических композициях и способах лечения состояний, для которых необходима модуляция дофаминовых рецепторов |
| HU230748B1 (hu) | 2007-05-11 | 2018-02-28 | Richter Gedeon Nyrt | Új piperazin só és előállítási eljárása |
| HUP0700353A2 (en) | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| EP2185155B1 (en) * | 2007-08-03 | 2017-10-04 | Richter Gedeon Nyrt. | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands |
| PL2317852T3 (pl) | 2008-07-16 | 2015-05-29 | Richter Gedeon Nyrt | Preparaty farmaceutyczne zawierające ligandy receptora dopaminy |
| US20110117214A1 (en) | 2009-11-16 | 2011-05-19 | Auspex Pharmaceuticals, Inc. | Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
| EP3079688B1 (en) | 2013-12-13 | 2017-11-22 | Pierre Fabre Medicament | A chromone derivative as a dopamine d3 receptor antagonist for its use in the treatment of autism spectrum disorder |
-
2019
- 2019-04-10 HU HUP1900121A patent/HU231500B1/hu unknown
-
2020
- 2020-03-11 TW TW109108018A patent/TW202103701A/zh unknown
- 2020-04-08 AR ARP200101001A patent/AR118634A1/es unknown
- 2020-04-09 DK DK20719737.7T patent/DK3952872T3/da active
- 2020-04-09 SI SI202030436T patent/SI3952872T1/sl unknown
- 2020-04-09 HU HUE20719737A patent/HUE066941T2/hu unknown
- 2020-04-09 LT LTEPPCT/IB2020/053382T patent/LT3952872T/lt unknown
- 2020-04-09 PL PL20719737.7T patent/PL3952872T3/pl unknown
- 2020-04-09 BR BR112021019367A patent/BR112021019367A2/pt unknown
- 2020-04-09 GE GEAP202015793A patent/GEP20237554B/en unknown
- 2020-04-09 EA EA202192717A patent/EA202192717A1/ru unknown
- 2020-04-09 SG SG11202110421YA patent/SG11202110421YA/en unknown
- 2020-04-09 HR HRP20240772TT patent/HRP20240772T1/hr unknown
- 2020-04-09 KR KR1020217036553A patent/KR20210151162A/ko active Search and Examination
- 2020-04-09 EP EP20719737.7A patent/EP3952872B1/en active Active
- 2020-04-09 FI FIEP20719737.7T patent/FI3952872T3/fi active
- 2020-04-09 CN CN202080027793.XA patent/CN113677345A/zh active Pending
- 2020-04-09 PT PT207197377T patent/PT3952872T/pt unknown
- 2020-04-09 RS RS20240573A patent/RS65530B1/sr unknown
- 2020-04-09 JP JP2021559605A patent/JP2022527386A/ja active Pending
- 2020-04-09 WO PCT/IB2020/053382 patent/WO2020208564A1/en active Application Filing
- 2020-04-09 AU AU2020271363A patent/AU2020271363A1/en active Pending
- 2020-04-09 ES ES20719737T patent/ES2980780T3/es active Active
- 2020-04-09 MX MX2021012321A patent/MX2021012321A/es unknown
- 2020-04-13 UY UY0001038657A patent/UY38657A/es unknown
-
2021
- 2021-10-07 IL IL287076A patent/IL287076A/en unknown
- 2021-10-08 CL CL2021002632A patent/CL2021002632A1/es unknown
- 2021-10-29 ZA ZA2021/08429A patent/ZA202108429B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY38657A (es) | 2020-10-30 |
| WO2020208564A1 (en) | 2020-10-15 |
| AR118634A1 (es) | 2021-10-20 |
| IL287076A (en) | 2021-12-01 |
| ES2980780T3 (es) | 2024-10-03 |
| PL3952872T3 (pl) | 2024-07-22 |
| HUE066941T2 (hu) | 2024-09-28 |
| EP3952872A1 (en) | 2022-02-16 |
| SI3952872T1 (sl) | 2024-07-31 |
| TW202103701A (zh) | 2021-02-01 |
| SG11202110421YA (en) | 2021-10-28 |
| BR112021019367A2 (pt) | 2021-12-07 |
| JP2022527386A (ja) | 2022-06-01 |
| HRP20240772T1 (hr) | 2024-09-13 |
| ZA202108429B (en) | 2022-09-28 |
| CN113677345A (zh) | 2021-11-19 |
| EP3952872B1 (en) | 2024-03-13 |
| RS65530B1 (sr) | 2024-06-28 |
| HU231500B1 (hu) | 2024-04-28 |
| KR20210151162A (ko) | 2021-12-13 |
| FI3952872T3 (fi) | 2024-06-12 |
| MX2021012321A (es) | 2021-11-12 |
| CL2021002632A1 (es) | 2022-05-06 |
| DK3952872T3 (da) | 2024-05-27 |
| GEP20237554B (en) | 2023-10-25 |
| HUP1900121A1 (hu) | 2020-10-28 |
| AU2020271363A1 (en) | 2021-11-18 |
| EA202192717A1 (ru) | 2022-01-17 |
| PT3952872T (pt) | 2024-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3297644A4 (en) | Methods for treating autism spectrum disorder and associated symptoms | |
| EP3245809A4 (en) | Architecture for simultaneous spectrum usage by air-to-ground and terrestrial networks | |
| EP3295602A4 (en) | Methods and apparatus for partial subframe transmission and broadcast channel on unlicensed spectrum | |
| EP3601563A4 (en) | ANALYSIS OF AUTISM SPECTRUM DISORDER | |
| WO2016179558A8 (en) | K-ras modulators | |
| EP3400010A4 (en) | ANTI-HER2 COMBINATIONS FOR THE TREATMENT OF TUMORS | |
| ZA202108429B (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| IL280128A (en) | A method for treating epilepsy | |
| EP3774743A4 (en) | PRODRUG COMPOUNDS ACTIVATED BY AKR1C3 AND USED IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | |
| EP3701946A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES WITH A COMPOUND BASED ON DITERPEN | |
| EP3595615A4 (en) | TREATMENT OF GINGIVITIS | |
| EP4048249A4 (en) | METHOD FOR TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | |
| EP3954368A4 (en) | LINK TO THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| EP3769759A4 (en) | AGENTS FOR TREATMENT OF EPILEPSY | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| EP3744332A4 (en) | AGENT INTENDED TO RELIEVE AUTISTIC SPECTRUM DISORDER AND MENTAL ILLNESS | |
| IL290319A (en) | Compound for combined treatment | |
| EP3948275A4 (en) | DIAGNOSIS OF CHILDREN'S RISK FOR AUTISTIC SPECTRUM DISEASE | |
| EP3854392A4 (en) | USE OF A CARBAMATE COMPOUND FOR THE PREVENTION, ATTENUATION OR TREATMENT OF CONCOMITANT EPILEPTIC SEIZURES | |
| EP4046637A4 (en) | EXTERNAL PREPARATION FOR THE TREATMENT OF EPILEPSY OR AN AUTISTIC SPECTRUM DISORDER | |
| GB201909466D0 (en) | Compounds for treating cancer | |
| EP3400939A4 (en) | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | |
| PT3921026T (pt) | Carotenoides c50 para o tratamento ou a prevenção da náusea | |
| EP3700632A4 (en) | METHOD OF TREATMENT OF ACUTE MYELOID LEUKEMIA | |
| EP3849605A4 (en) | METHODS OF TREATMENT OF PANCREATITIS |